Literature DB >> 30015962

Knockdown of metadherin inhibits cell proliferation and migration in colorectal cancer.

Jian-Wang Li1, Chun-Zhen Huang1, Jian-Hua Li2, Jian-Hua Yuan1, Qiong-Hui Chen1, Wei-Fang Zhang1, Zhen-Sheng Xu1, Ying-Ping Liu1, Yong Li3, Mei-Xiao Zhan3, Li-Gong Lu3.   

Abstract

Metadherin (MTDH) is a multifunctional oncogene involved in tumor cell migration and metastasis through regulating a number of oncogenic signaling pathways in various human malignancies. Previous studies have demonstrated that MTDH is overexpressed in human colorectal cancer (CRC) and associated with cancer progression and a poor prognosis. However, the underlying mechanisms remain largely unknown. The present study investigated the expression and role of MTDH in CRC cells as well as the underlying mechanism of this. Western blot analysis and quantitative polymerase chain reaction were conducted to determine protein and mRNA expression of MTDH in three human CRC cell lines. A short hairpin RNA (shRNA) targeting MTDH was introduced into CRC HCT116 cells to stably inhibit MTDH expression. A Cell Counting Kit‑8 assay, colony formation assay, Transwell assay and flow cytometry were used to investigate the effect of MTDH‑knockdown on cell proliferation, migration, apoptosis and cell cycle arrest. Western blotting was performed to examine the protein expression levels of cell growth‑ and apoptosis‑associated genes. The results demonstrated that MTDH was commonly expressed in CRC cell lines. MTDH silencing significantly suppressed cell growth, colony forming ability and migration while inducing the apoptosis of HCT116 cells. In addition, MTDH depletion induced S phase cell cycle arrest in HCT116 cells. Mechanistically, knockdown of MTDH markedly downregulated the expression of phosphorylated protein kinase B, c‑Myc, proliferating cell nuclear antigen and B‑cell lymphoma 2 (Bcl‑2) protein in HCT116 cells, and the expression of p53 and Bcl‑2‑associated X protein was significantly increased compared with the negative control shRNA group (P<0.05), suggesting that MTDH may function through the expression of numerous types of apoptosis‑associated and signaling channel proteins in CRC cells. Taken together, these data indicated that MTDH may serve as a biomarker and candidate therapeutic target for CRC.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30015962     DOI: 10.3892/or.2018.6581

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Integrated In Silico Analyses Identify PUF60 and SF3A3 as New Spliceosome-Related Breast Cancer RNA-Binding Proteins.

Authors:  Jennyfer M García-Cárdenas; Isaac Armendáriz-Castillo; Andy Pérez-Villa; Alberto Indacochea; Andrea Jácome-Alvarado; Andrés López-Cortés; Santiago Guerrero
Journal:  Biology (Basel)       Date:  2022-03-22

2.  Therapeutic Targeting of Metadherin Suppresses Colorectal and Lung Cancer Progression and Metastasis.

Authors:  Minhong Shen; Shanshan Xie; Michelle Rowicki; Sven Michel; Yong Wei; Xiang Hang; Liling Wan; Xin Lu; Min Yuan; John F Jin; Frank Jaschinski; Tianhua Zhou; Richard Klar; Yibin Kang
Journal:  Cancer Res       Date:  2020-11-25       Impact factor: 13.312

3.  Therapeutic strategies targeting Wnt/β‑catenin signaling for colorectal cancer (Review).

Authors:  Yong Ji; Jian Lv; Di Sun; Yufeng Huang
Journal:  Int J Mol Med       Date:  2021-10-29       Impact factor: 4.101

4.  Knockdown MTDH Inhibits Glioma Proliferation and Migration and Promotes Apoptosis by Downregulating MYBL2.

Authors:  Junqi Fu; Jun Peng; Guolong Tu
Journal:  Mediators Inflamm       Date:  2022-09-12       Impact factor: 4.529

5.  Phenethyl Isothiocyanate Suppresses Stemness in the Chemo- and Radio-Resistant Triple-Negative Breast Cancer Cell Line MDA-MB-231/IR Via Downregulation of Metadherin.

Authors:  Yen Thi-Kim Nguyen; Jeong Yong Moon; Meran Keshawa Ediriweera; Somi Kim Cho
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.